{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:52:41Z","timestamp":1792050761255,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014269","name":"Philippe Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021564","name":"Unicancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.breast.2026.104943","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:16:54Z","timestamp":1791904614000},"page":"104943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-9627","authenticated-orcid":false,"given":"Thomas","family":"Grinda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6793-3273","authenticated-orcid":false,"given":"Matthieu","family":"Carton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5284-9944","authenticated-orcid":false,"given":"Stefania","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0475-8631","authenticated-orcid":false,"given":"Audrey","family":"Mailliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-9484","authenticated-orcid":false,"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5269-1251","authenticated-orcid":false,"given":"Monica","family":"Arnedos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8094-4738","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Di\u00e9ras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6690-3535","authenticated-orcid":false,"given":"Vincent","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-5648","authenticated-orcid":false,"given":"Isabelle","family":"Desmoulins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-7439","authenticated-orcid":false,"given":"Anthony","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4188-3367","authenticated-orcid":false,"given":"Caroline","family":"Bailleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-0561","authenticated-orcid":false,"given":"Jean-Sebastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-9425","authenticated-orcid":false,"given":"Lise","family":"Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8178-6612","authenticated-orcid":false,"given":"Heather A.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-061X","authenticated-orcid":false,"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104943_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2026.111742","article-title":"Global burden, trends, and attributable risk factors of women's cancers with projection to 2050: results from the GLOBOCAN 2022 and global burden of disease study 2021","volume":"52","author":"Wei","year":"2026","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.breast.2026.104943_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.breast.2026.104943_bib3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104943_bib4","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2005.01.014","article-title":"Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104943_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104943_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab Deruxtecan plus pertuzumab for HER2-Positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104943_bib7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus Trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104943_bib8","doi-asserted-by":"crossref","first-page":"e1123","DOI":"10.1093\/oncolo\/oyad258","article-title":"Twenty-Year Follow-Up of a phase II trial of Taxotere\/Carboplatin\/Herceptin in patients with metastatic HER2-Positive breast cancer","volume":"28","author":"Gomez Marti","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104943_bib9","article-title":"Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours","volume":"6","author":"Pellat","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.breast.2026.104943_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023568","article-title":"The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME)","volume":"9","author":"Perol","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.breast.2026.104943_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100114","article-title":"Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort","volume":"6","author":"Grinda","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104943_bib12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.annpat.2014.08.018","article-title":"[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]","volume":"34","author":"Penault-Llorca","year":"2014","journal-title":"Ann Pathol"},{"key":"10.1016\/j.breast.2026.104943_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annpat.2021.07.014","article-title":"[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]","volume":"41","author":"Franchet","year":"2021","journal-title":"Ann Pathol"},{"key":"10.1016\/j.breast.2026.104943_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.annpat.2014.08.017","article-title":"[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]","volume":"34","author":"MacGrogan","year":"2014","journal-title":"Ann Pathol"},{"key":"10.1016\/j.breast.2026.104943_bib15","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1038\/bjc.2014.174","article-title":"Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER","volume":"110","author":"Yardley","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104943_bib16","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO2-04-01","article-title":"Abstract PO2-04-01: predictors of exceptional response to first line HER2-targeted therapy for metastatic breast cancer","volume":"84","author":"Morganti","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104943_bib17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.breast.2015.02.035","article-title":"Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: results from the French cohort study LHORA","volume":"24","author":"Spano","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104943_bib18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s10549-016-3705-3","article-title":"Clinical predictors of long-term survival in HER2-positive metastatic breast cancer","volume":"155","author":"Murthy","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104943_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s42003-025-07606-x","article-title":"Genomic hallmarks of endocrine therapy resistance in ER\/PR+HER2- breast tumours","volume":"8","author":"Ghosh","year":"2025","journal-title":"Commun Biol"},{"key":"10.1016\/j.breast.2026.104943_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101382","article-title":"193MO Development of a deep learning model using a large real-world database to predict overall survival in patients with metastatic breast cancer (MBC)","volume":"8","author":"Vuduc","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104943_bib21","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:16:04Z","timestamp":1792048564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":21,"alternative-id":["S0960977626002535"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104943","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features associated with exceptional response on first-line anti-HER2-based therapy for metastatic breast cancer: real-world data from the ESME national cohort","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104943"}}